DHEA for Lupus (SLE)

Unusually for a supplement, DHEA was tested in lupus as a candidate prescription drug, prasterone, in several large placebo-controlled trials [6]. A Cochrane review of seven randomised trials (842 participants) concluded it had little clinical effect on disease activity in mild to moderate lupus, measured by SLEDAI or SLAM, but a modest, clinically significant improvement in health-related quality of life, about 11.5 mm on a 100 mm patient global assessment scale [1].

The positive findings that exist are real but narrow. In women with active disease, 200 mg a day was linked to fewer flares in one trial [2], more successful prednisone tapering in another [3], and more patients improving or stabilising in a third [4]. In the trial built around fatigue, it did no better than placebo [5]. The FDA did not approve prasterone for lupus [6], and current EULAR guidance builds treatment on hydroxychloroquine, short steroid courses and immunosuppressive or biologic drugs instead [7].

Lupus is far more common in women, and hormones have long been suspected of playing a part. A 2026 meta-analysis of 83 studies found DHEA-S (the circulating, sulphated form of DHEA) was significantly lower in people with lupus than in healthy controls, by about 1.00 μg/mL, and described androgen deficiency as a consistent feature of the disease, particularly in women [8].

DHEA is a weak adrenal androgen that tissues convert into testosterone and, to a lesser extent, oestradiol. In the largest trial, testosterone rose and oestradiol rose less on 200 mg a day [4]. The theory was that restoring androgens would calm the overactive immune response.

In a 30-woman sub-study, 24 weeks of 200 mg DHEA lowered blood levels of IL-10, an immune signalling protein, from 9.21 to 1.89 pg/mL, while IL-1 beta did not change [9]. That is a laboratory marker, not a clinical result.

Low DHEA-S is also not proof that DHEA causes lupus activity, and topping it up did not reliably lower disease activity. In a Swedish trial, a low dose brought DHEA-S from subnormal to normal without any effect on disease activity [10]. At 200 mg a day, hormone levels go above the normal range [6], so the trials tested a drug dose, not a replacement.

Nearly every lupus trial used 200 mg of DHEA once a day [1][2][3][4][5]. One placebo-controlled trial also tested 100 mg, which did no better than placebo at allowing a steroid taper (44% vs 41%) [3]. A Swedish trial used a replacement dose of 30 mg a day for women aged 45 or younger and 20 mg for those 46 and older [10].

The large trials used prasterone, a proprietary synthetic DHEA product developed as a drug [6]. Over-the-counter DHEA supplements were not what was tested. Placebo-controlled trials ran for 3 to 12 months, always on top of standard lupus treatment such as antimalarials, low-dose prednisone and immunosuppressants [4]. If bone loss from steroids is your main worry, see also vitamin D for lupus.

The Cochrane review pooled seven randomised trials of at least three months, 842 participants in all. DHEA showed no benefit over placebo on SLEDAI in five of the six studies that reported it. Meta-analysis found a modest improvement in patient global assessment of 11.5 mm on a 100 mm scale, and acne was roughly twice as likely on DHEA (RR 2.2; 95% CI 1.65 to 2.83). The authors noted that long-term outcomes and safety remain unstudied [1].

A 2023 systematic review that included 13 lupus studies read the same literature more favourably, describing a mild to moderate effect on disease activity and a positive effect on bone density [14]. It did not pool results, and its finding of improved fatigue conflicts with the dedicated fatigue trial below, so the Cochrane meta-analysis remains the firmer guide [1][5].

The biggest trial enrolled 381 women at 27 centres. Among those with active disease (SLEDAI above 2), 58.5% on prasterone met a combined responder definition versus 44.5% on placebo (P = 0.017) [4]. The definition counted stabilisation as success, so it shows fewer women getting worse, not disease activity falling.

In 191 women on prednisone 10-30 mg a day, 55% on 200 mg prasterone sustained a taper to 7.5 mg or less, against 41% on placebo, which was not significant overall (P = 0.110). In the 137 with active disease, it was 51% versus 29% (P = 0.031) [3]. A Taiwanese trial of 120 women missed its primary end point (SLAM change -2.6 vs -2.0) but found fewer flares, 18.3% versus 33.9% (P = 0.044), and fewer serious adverse events, most of them flares [2].

Two early pilots set the stage. In 28 women with mild to moderate lupus, 3 months of 200 mg improved only the patient's own assessment significantly (P = 0.022) [15]. In 21 patients with severe lupus, 7 of 9 on DHEA responded versus 4 of 10 on placebo, which was not significant, and the DHEA group started sicker [16].

Fatigue, the symptom many people hope DHEA will fix, was tested directly in 60 women with inactive lupus. Both groups improved, with no difference between them, and the belief that one had taken DHEA predicted less fatigue better than actually taking it [5]. A systematic review of lupus fatigue treatments concluded DHEA is not recommended [17].

Bone results split. Over a year, 55 women on steroids gained 1.7% spine bone mineral density on prasterone and lost 1.1% on placebo (P = 0.003) [11]. A larger 155-woman trial found no significant difference in its 6-month placebo-controlled phase (P = 0.293); the later gains came from open-label treatment [12]. In 60 women with quiescent lupus, DHEA made no difference before menopause, though bone density rose in the small group of postmenopausal women not taking bone-protective drugs [18]. In the severe-lupus trial, spine density was maintained on DHEA and fell on placebo [16].

At 200 mg a day, the side effects are those of a male hormone. In the 381-woman trial, acne affected 33% on prasterone versus 14% on placebo, and hirsutism (unwanted hair growth) 16% versus 2%, though most cases were mild and did not require stopping treatment. Myalgia and mouth ulcers were less common on prasterone [4]. A pharmacology review also lists hypertension, blood in the urine and rises in serum creatinine [6], and mania has been reported with high-dose DHEA [19].

HDL cholesterol fell in several trials [4][10][13]. In a 13-woman crossover pilot, HDL was about 14% lower on prasterone than on placebo (48.5 vs 56.3), with a non-significant trend toward worse blood-vessel function, and the authors called the lipid effect potentially harmful [13]. That matters in lupus, where EULAR guidance includes preventing cardiovascular disease [7].

Because DHEA becomes testosterone and oestrogens, a pharmacology review flagged possible interactions with 5-alpha reductase inhibitors and additive or opposing effects with androgens, oestrogens, oral contraceptives and progestins [6]. Memorial Sloan Kettering advises against combining DHEA with tamoxifen, because the combination can lead to tamoxifen resistance [19]. None of these interactions was studied in the lupus trials, so treat them as reasons to tell your prescriber.